Zhaleh Safikhani
Zhaleh Safikhani
Post doctoral fellow
Verified email at utoronto.ca
Title
Cited by
Cited by
Year
PharmacoGx: an R package for analysis of large pharmacogenomic datasets
P Smirnov, Z Safikhani, N El-Hachem, D Wang, A She, C Olsen, ...
Bioinformatics 32 (8), 1244-1246, 2016
1382016
PharmacoDB: an integrative database for mining in vitro anticancer drug screening studies
P Smirnov, V Kofia, A Maru, M Freeman, C Ho, N El-Hachem, GA Adam, ...
Nucleic acids research 46 (D1), D994-D1002, 2018
742018
Revisiting inconsistency in large pharmacogenomic studies
Z Safikhani, P Smirnov, M Freeman, N El-Hachem, A She, Q Rene, ...
F1000Research 5, 2016
652016
Consistency in drug response profiling: reply
Z Safikhani, N El-Hachem, P Smirnov, M Freeman, A Goldenberg, ...
Nature 540 (7631), E6-E8, 2016
58*2016
Public data and open source tools for multi-assay genomic investigation of disease
L Kannan, M Ramos, A Re, N El-Hachem, Z Safikhani, DMA Gendoo, ...
Briefings in bioinformatics 17 (4), 603-615, 2016
542016
Drug response consistency in CCLE and CGP: reply
Z Safikhani, N El-Hachem, P Smirnov, M Freeman, A Goldenberg, ...
Nature 540 (7631), E11-E12, 2016
48*2016
Consensus on molecular subtypes of high-grade serous ovarian carcinoma
GM Chen, L Kannan, L Geistlinger, V Kofia, Z Safikhani, DMA Gendoo, ...
Clinical Cancer Research 24 (20), 5037-5047, 2018
442018
Gene isoforms as expression-based biomarkers predictive of drug response in vitro
Z Safikhani, P Smirnov, KL Thu, J Silvester, N El-Hachem, R Quevedo, ...
Nature Communications 8 (1), 1126, 2017
382017
Abstract: Gene isoforms as expression-based biomarkers predictive of drug response in vitro
Z Safikhani, KL Thu, P Smironov, B Haibe-Kains
Annals of Oncology 28 (suppl_1), 2017
38*2017
Consistency in large pharmacogenomic studies: reply
Z Safikhani, N El-Hachem, P Smirnov, M Freeman, A Goldenberg, ...
Nature 540 (7631), E2-E4, 2016
37*2016
Disruption of the anaphase-promoting complex confers resistance to TTK inhibitors in triple-negative breast cancer
KL Thu, J Silvester, MJ Elliott, W Ba-Alawi, MH Duncan, AC Elia, AS Mer, ...
Proceedings of the National Academy of Sciences 115 (7), E1570-E1577, 2018
362018
Integrative cancer pharmacogenomics to infer large-scale drug taxonomy
N El-Hachem, DMA Gendoo, LS Ghoraie, Z Safikhani, P Smirnov, ...
Cancer research 77 (11), 3057-3069, 2017
332017
Assessment of pharmacogenomic agreement
Z Safikhani, N El-Hachem, R Quevedo, P Smirnov, A Goldenberg, ...
F1000Research 5, 2016
302016
Machine learning approaches to drug response prediction: challenges and recent progress
G Adam, L Rampášek, Z Safikhani, P Smirnov, B Haibe-Kains, ...
NPJ precision oncology 4 (1), 1-10, 2020
242020
Tissue specificity of in vitro drug sensitivity
F Yao, SA Madani Tonekaboni, Z Safikhani, P Smirnov, N El-Hachem, ...
Journal of the American Medical Informatics Association 25 (2), 158-166, 2018
182018
SSP: An interval integer linear programming for de novo transcriptome assembly and isoform discovery of RNA-seq reads
Z Safikhani, M Sadeghi, H Pezeshk, C Eslahchi
Genomics 102 (5-6), 507-514, 2013
102013
Consensus on molecular subtypes of ovarian cancer
GM Chen, L Kannan, L Geistlinger, V Kofia, Z Safikhani, DMA Gendoo, ...
bioRxiv, 162685, 2017
62017
The antiarrhythmic drug, dronedarone, demonstrates cytotoxic effects in breast cancer independent of thyroid hormone receptor alpha 1 (THRα1) antagonism
MJ Elliott, KJ Jerzak, JG Cockburn, Z Safikhani, WD Gwynne, JA Hassell, ...
Scientific reports 8 (1), 1-10, 2018
52018
Assessment of genetic drift in large pharmacogenomic studies
R Quevedo, P Smirnov, D Tkachuk, C Ho, N El-Hachem, Z Safikhani, ...
Cell Systems 11 (4), 393-401. e2, 2020
22020
ORCESTRA: a platform for orchestrating and sharing high-throughput pharmacogenomic analyses
A Mammoliti, P Smirnov, M Nakano, Z Safikhani, C Ho, G Beri, ...
bioRxiv, 2020
22020
The system can't perform the operation now. Try again later.
Articles 1–20